<!DOCTYPE html>
<html>
<head>
  <!-- Site made with Mobirise Website Builder v3.11.1, https://mobirise.com -->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Mobirise v3.11.1, mobirise.com">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link rel="shortcut icon" href="assets/images/logo.png" type="image/x-icon">
  <meta name="description" content="Website Builder Description">
  <title>Website Builder Title</title>
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lora:400,700,400italic,700italic&amp;subset=latin">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Raleway:100,100i,200,200i,300,300i,400,400i,500,500i,600,600i,700,700i,800,800i,900,900i">
  <link rel="stylesheet" href="assets/bootstrap-material-design-font/css/material.css">
  <link rel="stylesheet" href="assets/tether/tether.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/soundcloud-plugin/style.css">
  <link rel="stylesheet" href="assets/dropdown/css/style.css">
  <link rel="stylesheet" href="assets/animate.css/animate.min.css">
  <link rel="stylesheet" href="assets/theme/css/style.css">
  <link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css">
  
  
  
</head>
<body>
<section id="menu-2a">

    <nav class="navbar navbar-dropdown bg-color transparent">
        <div class="container">

            <div class="mbr-table">
                
                <div class="mbr-table-cell">

                    <button class="navbar-toggler pull-xs-right hidden-md-up" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                        <div class="hamburger-icon"></div>
                    </button>

                    <ul class="nav-dropdown collapse pull-xs-right nav navbar-nav navbar-toggleable-sm" id="exCollapsingNavbar"><li class="nav-item"><a class="nav-link link" href="index.html">HOME&nbsp;</a></li><li class="nav-item"><a class="nav-link link" href="Introduction.html">OVERVIEW&nbsp;</a></li><li class="nav-item"><a class="nav-link link" href="Programme.html">PROGRAMME&nbsp;</a></li></ul>
                    <button hidden="" class="navbar-toggler navbar-close" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                        <div class="close-icon"></div>
                    </button>

                </div>
            </div>

        </div>
    </nav>

</section>

<section class="engine"><a rel="external" href="https://mobirise.com">Mobirise Website Maker</a></section><section class="mbr-section article mbr-section__container mbr-after-navbar" id="content1-2b" style="background-color: rgb(255, 255, 255); padding-top: 120px; padding-bottom: 0px;">

    <div class="container">
        <div class="row">
            <div class="col-xs-12 lead"><p><strong>NRF2 Associated Immune Evasion in Non-Small Cell Lung&nbsp;</strong><strong>Cancer and Squamous Malignancies&nbsp;</strong></p><p><strong><br></strong></p><p>Anna-Liisa Levonen</p><p><br></p><p>A.I.Virtanen Insitute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Finland</p><p><strong>Email: </strong>anna-liisa.levonen@uef.fi</p><p><strong><br></strong></p><p>The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a robust NRF2 activity metric and utilized it to conduct a pan-cancer wide analysis of oncogenic NRF2 signaling. We identified a distinct immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T-cell infiltration spanning non-small cell lung cancer (NSCLC) and squamous malignancies of head and neck area, cervix and esophagus. In squamous cell cancers, NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune-cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11 and SLC2A1 that represent candidate NRF2 target genes, suggesting direct modulation of the tumor immune milieu. Based on single-cell mRNA data, coupled with a priori information on intercellular ligand-receptor interactions, cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. As we observed differential cytokine mRNA expression with IFNγ treatment in NSCLC adenocarcinoma subtype, we explored the cytokine secretome in vitro. We found that secreted neutrophil chemoattractants interleukin-8 (CXCL8) and ENA-78 (CXCL5) are elevated in NRF2 overactive cells, suggesting contribution of immunosuppressive neutrophils in NRF2 driven immune escape.&nbsp;</p><p>Importantly, as overactive NRF2 is associated with immune-cold characteristics, our results&nbsp;</p><p>highlight the utility of NRF2 pathway activation for stratifying immune checkpoint blockade responders and non-responders across NSCLC and squamous cancers. Given that in NSCLC NRF2 pathway activation is largely due to somatic mutations in either KEAP1 or NFE2L2, identification of mutations of these genes from cell free DNA may provide a simple and non-invasive method for patient stratification.</p><p><strong><br></strong></p><p><strong><br></strong></p></div>
        </div>
    </div>

</section>

<section class="mbr-section" id="msg-box5-2c" style="background-color: rgb(255, 255, 255); padding-top: 0px; padding-bottom: 0px;">

    
    <div class="container">
        <div class="row">
            <div class="mbr-table-md-up">

              <div class="mbr-table-cell mbr-right-padding-md-up mbr-valign-top col-md-7 image-size" style="width: 28%;">
                  <div class="mbr-figure"><img src="assets/images/anna-liisa-1400x1509.jpg"></div>
              </div>

              


              <div class="mbr-table-cell col-md-5 text-xs-center text-md-left content-size">
                  
                  <div class="lead">

                    <p><strong>Anna-Liisa Levonen</strong>&nbsp;is currently Professor and Vice Dean of Research at the University of Eastern Finland, Faculty of Health Sciences. She earned her MD and PhD degrees from the University of Helsinki, Finland in 1994 and 2000, respectively, followed by a fellowship at the University of Alabama at Birmingham (UAB), Department of Pathology and Center for Free Radical Biology. Upon her return to Finland, she was recruited to the University of Kuopio (currently University of Eastern Finland), where she has established a research program focusing on the gene regulatory mechanisms activated by oxidative and electrophilic stress, particularly via the redox-activated transcription factor NRF2. She has studied the mechanism of activation of the KEAP1-NRF2 pathway and its role in disease, particularly cancer and cardiometabolic diseases, and has published highly cited original and review articles on the topic.</p>

                  </div>

                  
              </div>


              

            </div>
        </div>
    </div>

</section>


  <script src="assets/web/assets/jquery/jquery.min.js"></script>
  <script src="assets/tether/tether.min.js"></script>
  <script src="assets/bootstrap/js/bootstrap.min.js"></script>
  <script src="assets/smooth-scroll/SmoothScroll.js"></script>
  <script src="assets/dropdown/js/script.min.js"></script>
  <script src="assets/touchSwipe/jquery.touchSwipe.min.js"></script>
  <script src="assets/viewportChecker/jquery.viewportchecker.js"></script>
  <script src="assets/theme/js/script.js"></script>
  
  
  <input name="animation" type="hidden">
  </body>
</html>